RNA transfection

EQS-News: CureVac Named as One of the World’s Most Dynamic Innovators by LexisNexis®

Retrieved on: 
Thursday, February 2, 2023
Momentum, COVID-19, RNA transfection, Public health, CVAC, Invention, Vaccine, Therapy, Patent, CureVac, Science

The Top 100 recognizes companies advancing innovative solutions to address today’s challenges and laying the intellectual property foundations for further breakthroughs.

Key Points: 
  • The Top 100 recognizes companies advancing innovative solutions to address today’s challenges and laying the intellectual property foundations for further breakthroughs.
  • The LexisNexis® report identifies companies shaping the future of science and technology by analyzing shifts in patent portfolio strength over the last two years.
  • We continue to invest in innovations in this rapidly developing field to further grow the value of our extensive portfolio.
  • Patented CureVac technologies are the basis for multiple advances without which the breakthrough of mRNA-based therapy would not have been possible.

EQS-News: CureVac Announces Positive Data in Older Adults from COVID-19 and Flu mRNA Vaccine Development Programs

Retrieved on: 
Thursday, February 2, 2023
WHO, Influenza, Infection, Omicron, Safety, GSK, RNA transfection, CureVac, CVAC, COVID-19, Vaccine

The data further support the decision to advance updated versions of the modified mRNA COVID-19 and flu vaccine constructs to the next stage of clinical testing in 2023.

Key Points: 
  • The data further support the decision to advance updated versions of the modified mRNA COVID-19 and flu vaccine constructs to the next stage of clinical testing in 2023.
  • “The exciting preliminary data seen among older adults for our COVID-19 and flu programs significantly add to the validation of our technology platform into this highly relevant and at-risk population,” said Franz-Werner Haas, Chief Executive Officer of CureVac.
  • The vaccine candidate for future clinical development is expected to target all four flu virus strains currently recommended by the WHO for influenza vaccines.
  • In 2022, the companies broadened their development strategy to test modified mRNA in addition to unmodified mRNA.

EQS-News: CureVac Welcomes Myriam Mendila as New Chief Development Officer

Retrieved on: 
Thursday, February 2, 2023
Medical school, Roche, RNA transfection, COVID-19, Novartis, CVAC, Medical Affairs Bureau, Infection, Genentech, CureVac, Interim, Pharmacovigilance, Pharmaceutical industry, MD

TÜBINGEN, Germany/ BOSTON, USA – February 1, 2023 – CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced that Myriam Mendila has taken up her role as CureVac’s Chief Development Officer, as previously announced .

Key Points: 
  • TÜBINGEN, Germany/ BOSTON, USA – February 1, 2023 – CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced that Myriam Mendila has taken up her role as CureVac’s Chief Development Officer, as previously announced .
  • “Myriam’s extensive expertise in product development in the global pharmaceutical industry, particularly the past several years in oncology, will be a significant asset to CureVac as we continue to advance our mRNA product pipeline.
  • On behalf of the entire team, I would like to offer Myriam a very warm welcome as a new member of CureVac’s management,” said Franz-Werner Haas, Chief Executive Offer at CureVac.
  • “I would also like to extend my wholehearted thanks to Ulrike Gnad-Vogt for stepping in as Interim Chief Development Officer during the past eight months.”
    “I’m truly excited to join CureVac at this important inflection point of the company,” said Dr. Mendila.

hC Bioscience and 4SR Biosciences Join Forces to Expand Platform Development of tRNA-Based Therapies

Retrieved on: 
Tuesday, January 17, 2023
Tao, Molecular biology, RNA transfection, Associate, SAB, University, Biology, Therapy, Biochemistry, Cancer, IP, Acquisition, Chicago (franchise), United States Air Force Scientific Advisory Board, Content discovery platform, Pharmaceutical industry, Telescopic sight

Cambridge, Massachusetts--(Newsfile Corp. - January 17, 2023) - hC Bioscience, a pioneer in the development of tRNA-based therapeutics, has acquired 4SR Biosciences to combine technologies, IP, and know-how to advance the development of first-in-class tRNA-based therapeutics.

Key Points: 
  • Cambridge, Massachusetts--(Newsfile Corp. - January 17, 2023) - hC Bioscience, a pioneer in the development of tRNA-based therapeutics, has acquired 4SR Biosciences to combine technologies, IP, and know-how to advance the development of first-in-class tRNA-based therapeutics.
  • As part of the acquisition, Tao Pan, Ph.D., Professor of Biochemistry and Molecular Biology and a pioneer in tRNA technology and biology, will join hC Bioscience as a scientific advisor and member of its Scientific Advisory Board, Christopher Katanski, Ph.D., will join hC Bioscience as Director of Discovery Platform and Philip McGilvray, Ph.D., will join as Associate Director of Discovery Platform.
  • hC Bioscience and 4SR Biosciences consolidate complementary technologies, IP and know-how related to the design and development of tRNA-based therapies.
  • Tao Pan, Ph.D., Professor of Biochemistry and Molecular Biology at the University of Chicago to join hC Bioscience as a scientific advisor and member of the SAB; Christopher Katanski, Ph.D. to join hC Bioscience as Director of Discovery Platform and Philip McGilvray, Ph.D. to join as Associate Director of Discovery Platform.

Omega Therapeutics to Present Trial-in-Progress Poster for Phase 1/2 MYCHELANGELO™ I Study at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium

Retrieved on: 
Tuesday, January 17, 2023
Therapy, RNA transfection, MYC, Standard of care, Pharmacokinetics, Hepatocellular carcinoma, Safety, Poster, Gastrointestinal cancer, Patient, OEC, HCC, Society, American Society of Clinical Oncology, Pharmaceutical industry, Dietary supplement

CAMBRIDGE, Mass., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenetic mRNA medicines, today announced that it will present a trial-in-progress poster at the upcoming American Society for Clinical Oncology 2023 Gastrointestinal Cancers Symposium (ASCO-GI), taking place in San Francisco, Calif., and virtually, January 19–21, 2023.

Key Points: 
  • CAMBRIDGE, Mass., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenetic mRNA medicines, today announced that it will present a trial-in-progress poster at the upcoming American Society for Clinical Oncology 2023 Gastrointestinal Cancers Symposium (ASCO-GI), taking place in San Francisco, Calif., and virtually, January 19–21, 2023.
  • The poster will highlight the design of the ongoing MYCHELANGELO™ I study, a Phase 1/2 open-label trial evaluating OTX-2002, a first-in-class Omega Epigenomic Controller™ (OEC) candidate, for the treatment of hepatocellular carcinoma (HCC) and other solid tumor types known for association with the c-Myc (MYC) oncogene.
  • Details for the ASCO Gastrointestinal Cancers Symposium Trial-in-Progress poster presentation are as follows:
    Title: A phase 1/2 open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of OTX-2002 as a single agent and in combination with standard of care in patients with hepatocellular carcinoma and other solid tumor types known for association with the MYC oncogene (MYCHELANGELO I).
  • The poster will be made available on the Omega website at https://omegatherapeutics.com/our-science/#publications-research at the same time as the presentation.

Avectas Launches the Solupore® Platform for the Clinical Manufacturing of Next-Generation Gene-Modified Cell Therapies with Unparalleled Cell Health and Functionality

Retrieved on: 
Monday, January 16, 2023
RNP, Data, Cell engineering, Plasmid, RNA transfection, Cas9, Cell membrane, Patient, Ministry of Education (Malaysia), Doctor of Philosophy, Potency (pharmacology), Transfection, GenScript Biotech, GMP, Vaccine, Pharmaceutical industry

Solupore technology works by temporarily permeabilizing the target cell membrane so that molecular cargoes such as mRNA, plasmids, RNP or CRISPR/Cas9 can be delivered while retaining superior cell health and function.

Key Points: 
  • Solupore technology works by temporarily permeabilizing the target cell membrane so that molecular cargoes such as mRNA, plasmids, RNP or CRISPR/Cas9 can be delivered while retaining superior cell health and function.
  • Launching our clinical manufacturing system brings us closer to fulfilling our vision of working with partners to accelerate the future of cell therapies for patients."
  • Caption: Solupore clinical manufacturing system for non-viral delivery to enable next-generation cell therapies.
  • Provides unparalleled cell health and superior cell functionality, expanding the possibilities for complex editing and challenging cargo delivery
    Easy to integrate into existing GMP processes, Solupore accelerates the translation of life-saving therapies to patients

Altamira Therapeutics to Present at 2nd Annual mRNA-Based Therapeutics Summit Europe Conference January 24th to 26th

Retrieved on: 
Tuesday, January 10, 2023
Altamira, Tissue, RNA transfection, Semaphore, LNP, Conference, Protein, Therapy, RNA, Research, Medicine, Liver, Cytoplasm, Medical device, Vaccine

Altamira is developing the use of mRNA to therapeutically increase the local production of specific proteins outside the liver to treat a variety of diseases.

Key Points: 
  • Altamira is developing the use of mRNA to therapeutically increase the local production of specific proteins outside the liver to treat a variety of diseases.
  • For this purpose, the Company is using its SemaPhore platform to efficiently transport those mRNA payloads into extrahepatic target cells.
  • Even the most powerful mRNA molecule is useless, however, if it cannot be delivered safely and effectively to the target tissue.
  • With our SemaPhore platform, we have the right technology to take mRNA where it is needed and release it efficiently inside target cells.”

GreenLight Biosciences and Epivax Therapeutics Sign Exclusive Collaboration Agreement to Develop Personalized Cancer Vaccines

Retrieved on: 
Monday, January 9, 2023
COVID-19, CD8, Cancer, Algorithm, Therapy, RNA transfection, Epitope, Biotechnology, GRNA, Vaccine, Bladder cancer, Partnership, CD4, PBC, Serum Institute of India, Samsung Biologics, Patient, RNA, Research, Abraham Ancer, Shingles, NIH, Green-light

Under this collaboration, the companies will design and develop new personalized mRNA cancer vaccine candidates using GreenLight and EpiVax Therapeutics technology platforms.

Key Points: 
  • Under this collaboration, the companies will design and develop new personalized mRNA cancer vaccine candidates using GreenLight and EpiVax Therapeutics technology platforms.
  • EpiVax Therapeutics was the first personalized vaccine company to use computational tools to identify tolerogenic epitopes in neoantigens and to exclude these from cancer vaccine designs.
  • Together, GreenLight and EpiVax Therapeutics will leverage their respective expertise and jointly develop and commercialize potential novel personalized mRNA-based vaccine candidates for a wide range of oncology indications.
  • “We are delighted to partner with EpiVax Therapeutics, to expedite development of personalized cancer vaccine candidates using GreenLight’s RNA platform,” said Andrey Zarur, CEO of GreenLight.

Ocugen Announces Positive Top-Line Data for COVID-19 Vaccine Candidate COVAXIN™ (BBV152) in Phase 2/3 Immuno-bridging and Broadening Study: Both Co-primary Endpoints Met

Retrieved on: 
Monday, January 9, 2023
RBD, COVID-19, RNA transfection, SAE, Severe acute respiratory syndrome coronavirus 2, Safety, Bharat Biotech, Vaccination, Vaccine, New England Complex Systems Institute, Pericarditis, Myocarditis, Body mass index, ClinicalTrials.gov, Antigen, Seroconversion, BBV152, Pharmaceutical industry

“The successful completion of this study represents an important milestone to the ongoing management of COVID-19,” said Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-Founder of Ocugen.

Key Points: 
  • “The successful completion of this study represents an important milestone to the ongoing management of COVID-19,” said Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-Founder of Ocugen.
  • Blinded safety results and preliminary unblinded immunogenicity results are available through Day 56, one month following the second vaccination.
  • Approximately 24% of tested participants in the U.S. were vaccine-naïve while all participants in the Bharat Biotech Phase 3 study were vaccine-naïve.
  • There were no deaths, related potential immune mediated medical conditions (PIMMCs), or related adverse events of special interest (AESIs).

Tessera Therapeutics Highlights Advancements Across its Gene Writing™ and Delivery Platforms Including Proof of Concept Data in Non-Human Primates

Retrieved on: 
Monday, January 9, 2023
Phenylketonuria, Genome, Cell, Gene, PST, Flagship Pioneering, Therapy, Tissue, Biochemistry, AAV, Biotechnology, Health, DNA, PKU, Mutation, LNP, Conference, Stem cell, Disease, Hepatectomy, Exon, CAR, NHP, Allele, RNA transfection, Liver, Reverse transcriptase, Genetic distance, Sickle cell disease, Vaccine, Tessera

“Our preclinical studies demonstrate that we can deliver our Gene Writers to the right location, in the liver and beyond, and make therapeutic alterations to the genome.

Key Points: 
  • “Our preclinical studies demonstrate that we can deliver our Gene Writers to the right location, in the liver and beyond, and make therapeutic alterations to the genome.
  • The Company’s proprietary non-viral lipid nanoparticles (LNPs) are designed to deliver Gene Writers™ to targeted tissues, potentially enabling the application of Gene Writing™ therapies in vivo.
  • DNA Gene Writers™ are based on recombinase or transposase element biochemistry and have been engineered to integrate a therapeutically relevant payload of choice.
  • Additional data demonstrate the ability to write longer sequences and entire genes with high efficiency and specificity.